Previous Close
Price To Book
Market Cap
Shares 0
Volume 0
Short Ratio
Av. Daily Volume 0

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved April 30, 2010.
Gastric ulcers
Approval announced September 15, 2016.
YOSPRALA (PA32540/PA8140)
Secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers

Latest News

  1. [$$] Aralez in Stalking Horse Deals With Nuvo, Deerfield
  2. Aralez Pharmaceuticals To Enter Into Purchase Agreements To Sell Substantially All Assets
  3. Aralez Enters Into Amendment To Second Amended And Restated Facility Agreement
  4. Aralez Announces Voting Results From 2018 Annual Meeting Of Shareholders
  5. Anthera Pharma and Three Additional Stocks Under Scanner in the Biotech Space
  6. Interested In Aralez Pharmaceuticals Inc (TSE:ARZ)? Here’s How It Performed Recently
  7. Free Daily Technical Summary Reports on Amicus Therapeutics and Three Other Biotech Stocks
  8. Is There An Opportunity With Aralez Pharmaceuticals Inc’s (TSE:ARZ) 39% Undervaluation?
  9. Edited Transcript of ARLZ earnings conference call or presentation 8-May-18 12:00pm GMT
  10. Today’s Research Reports on Stocks to Watch: Amedica Corporation and Aralez Pharmaceuticals
  11. Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway
  12. Aralez Pharmaceuticals: 1Q Earnings Snapshot
  13. Aralez Announces First Quarter 2018 Financial Results
  14. Aralez Announces New Strategic Direction
  15. Aralez To Announce First Quarter 2018 Results On May 8, 2018
  16. Edited Transcript of ARLZ earnings conference call or presentation 13-Mar-18 12:30pm GMT
  17. Will Aralez Pharmaceuticals Inc’s (TSE:ARZ) Earnings Grow In The Next Couple Of Years?
  18. ARLZ: Aralez Set for Strong Revenue Growth in 2018

SEC Filings

  1. 8-K - Current report 181231069
  2. 8-K - Current report 181157991
  3. 8-K - Current report 181110856
  4. 8-K - Current report 181098101
  5. 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
  6. 8-K - Current report 181078287
  7. 8-K - Current report 181018923
  8. 8-K - Current report 18972124
  9. 8-K - Current report 18930072
  10. 8-K - Current report 18930018